Kiniksa Pharmaceuticals International PLC

The mid-August Momentum Breakout confirms medium-term bullish asymmetry, but the recent pullback below the 9- and 20-day EMAs alongside a declining RSI signals short-term hesitation. Price remains above the rising 50-day SMA and 200-day SMA, preserving the broader uptrend. Execution should be deferred until price shows acceptance near the 50-day SMA, with a reclaim of the 20-day EMA providing renewed entry readiness.

• ↑Q4 2025 ARCALYST revenue hit $202.1 M (+65% YoY); FY 2025 total $677.6 M (+62%)
• ↑Raised full-year 2026 net revenue outlook to $900–920 M after robust Q2
• ↓Valuation risk: weak earnings yield and low book-to-price metrics suggest limited upside